Vitamin c boost: could it make chemo safer for myeloma patients?

NCT ID NCT06313502

Recruiting now Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three prior treatments. The goal is to see if the vitamin C can help the lower chemo dose work better while causing fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: high-dose vitamin C (ascorbic acid) plus reduced-dose melphalan chemotherapy
What this could lead to: If it works, this could point toward a less toxic treatment option for relapsed multiple myeloma, using high-dose vitamin C to boost the effects of lower-dose chemotherapy.
What could go wrong: This is a very early Phase 1 trial with only 18 people, so it is too soon to know if it works or is safe. High-dose vitamin C can cause side effects like kidney stones or infusion reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLASMA CELL DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLASMA CELL DISORDER

Contacts and locations

Locations

University of Arkansas for Medical Sciences
RECRUITING

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.